2025 Japan Attention-Deficit Hyperactivity Disorder Revenue Opportunities Report
Description
The 2025 Japan Attention-Deficit Hyperactivity Disorder Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Attention-Deficit Hyperactivity Disorder by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the ADHD market in Japan are Shire Japan, Novartis Pharma, Janssen Pharmaceutical, and Pfizer Japan. These companies dominate the market by offering a wide range of ADHD medications, including stimulants like methylphenidate and non-stimulants like atomoxetine, which are commonly prescribed in Japan. Takeda Pharmaceutical and Eisai Co. Ltd. are also significant players, with Takeda involved in the ADHD medication market.
Additionally, Shionogi & Co., Ltd. has recently become prominent in Japan through its commercialization of Akili's digital therapeutic app ENDEAVORRIDE (SDT-001), a novel non-drug treatment for pediatric ADHD. This digital therapeutic was approved in Japan in 2025 and represents a new modality alongside traditional pharmacological treatments. Shionogi holds exclusive rights for this therapy in Japan and Taiwan, backed by successful Phase III clinical trials demonstrating symptom improvement in children with ADHD. This positions Shionogi uniquely as a leader in innovative ADHD interventions in Japan.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Attention-Deficit Hyperactivity Disorder by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the ADHD market in Japan are Shire Japan, Novartis Pharma, Janssen Pharmaceutical, and Pfizer Japan. These companies dominate the market by offering a wide range of ADHD medications, including stimulants like methylphenidate and non-stimulants like atomoxetine, which are commonly prescribed in Japan. Takeda Pharmaceutical and Eisai Co. Ltd. are also significant players, with Takeda involved in the ADHD medication market.
Additionally, Shionogi & Co., Ltd. has recently become prominent in Japan through its commercialization of Akili's digital therapeutic app ENDEAVORRIDE (SDT-001), a novel non-drug treatment for pediatric ADHD. This digital therapeutic was approved in Japan in 2025 and represents a new modality alongside traditional pharmacological treatments. Shionogi holds exclusive rights for this therapy in Japan and Taiwan, backed by successful Phase III clinical trials demonstrating symptom improvement in children with ADHD. This positions Shionogi uniquely as a leader in innovative ADHD interventions in Japan.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
